Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma

Ikue Okamura, Hisao Imai, Keita Mori, Kazuto Ogura, Atsushi Isoda, Keichiro Mihara, Morio Matsumoto, Ryusei Saito, Toshiaki Takahashi, Takashi Ikeda

研究成果: Article査読

14 被引用数 (Scopus)

抄録

Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare extranodal lymphoma with a 5-year survival rate of 80–95 %. There is no standard treatment strategy for pulmonary MALT lymphoma. In the present study, we performed a retrospective evaluation of systemic rituximab monotherapy (375 mg m−2 day−1, 4–8 cycles) as first-line treatment in patients with pulmonary MALT lymphoma. Of the eight patients enrolled, five achieved complete response, one achieved partial response, and two showed stable disease. Median progression-free survival was 66.0 months (range 9.7–87.2 months). Treatment was well tolerated and all patients were alive during the median follow-up period of 64.0 months. Rituximab monotherapy was efficacious in patients with pulmonary MALT lymphoma, demonstrating long-term disease stabilization and symptom reduction. Larger prospective studies are warranted to further assess the efficacy of rituximab monotherapy. In conclusion, rituximab monotherapy may be considered for first-line therapy in patients with pulmonary MALT lymphoma.

本文言語English
ページ(範囲)46-51
ページ数6
ジャーナルInternational Journal of Hematology
101
1
DOI
出版ステータスPublished - 01-2014
外部発表はい

All Science Journal Classification (ASJC) codes

  • 血液学

フィンガープリント

「Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル